Personal Genome Diagnostics (PGDx) has raised $103 million in series C financing; the company plans to use the funds to expand its tissue-based and liquid biopsy portfolio and its global commercial footprint to garner continued growth.
The added commercial and operational infrastructure will enable broader access to and adoption of the firm's Elio oncology products, while supporting its pharma and biotechnology partnerships in identifying cancer biomarker targets and accelerating biomarker-driven therapy development.
